SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Dominic Walsh, Ph.D., VP Alzheimer's dis
Drug Development
Biogen Successfully Targets Tau in Phase Ib Alzheimer’s Study
BIIB080 successfully reduced tau pathology in patients with early-stage disease across all six brain regions analyzed.
March 30, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Mihael Polymeropoulos, CEO, Vanda Pharma
Policy
Court Sides with Vanda Against FDA in Freedom of Information Act Case
A federal court sided in favor of Vanda Pharmaceuticals in its Freedom of Information Act case against the FDA regarding the CRL for its sleep drug label expansion.
March 30, 2023
 · 
3 min read
 · 
Kate Goodwin
Onivyde failed in the trial of late-stage small ce
Drug Development
ArriVent Snags $155M for NSCLC Treatment in Record Low Series B Period
Despite a tough financing market, ArriVent Biopharma closed a $155 million Series B to fund a pivotal Phase III trial of its non-small cell lung cancer asset.
March 27, 2023
 · 
2 min read
 · 
Kate Goodwin
A woman with her head in her hands/Courtesy of Shu
Drug Development
Latest Data for Karuna’s Schizophrenia Drug Spark Investor Concern
Analysts point to a missed secondary endpoint and cardiovascular risks that may delay FDA approval as possible reasons for the unexpected drop in Karuna’s stock following the data reveal.
March 24, 2023
 · 
4 min read
 · 
Kate Goodwin
Sarah Silbiger/Getty Images
FDA
Cidara and Melinta Win FDA Approval for First New Echinocandin in a Decade
Wednesday, the FDA approved Cidara Therapeutics and Melinta Therapeutics’ Rezzayo (rezafungin) injection to treat candidemia and invasive candidiasis.
March 23, 2023
 · 
2 min read
 · 
Kate Goodwin
Pierre Suu/Getty Images
Drug Development
Pfizer and Astellas Seek Expanded Label for Expensive Prostate Cancer Drug
Pfizer and Astellas announced positive topline Phase III results Thursday for Xtandi plus leuprolide in non-metastatic castration-sensitive prostate cancer.
March 17, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Seamless Therapeutics' Anne-Kristin Heni
Business
Seamless Launches with $12.5M for Programmable Recombinases Platform
Seamless Therapeutics launched Wednesday with $12.5 million in seed financing to develop its programmable recombinases for gene editing.
March 16, 2023
 · 
2 min read
 · 
Kate Goodwin
Rahul Ballal, Ph.D., CEO, Mediar Therapeutics/cour
Business
Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift
Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.
March 15, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Financing concept/Getty Images
Drug Development
Amplifier Launches to Bring First AMPK Activator to the Clinic
Cambrian BioPharma announced the launch of Amplifier Therapeutics, a biotech focused on developing a clinical-stage AMPK activator.
March 14, 2023
 · 
2 min read
 · 
Kate Goodwin
Pierre Suu/Getty Images
Deals
Pfizer Wins Seagen Sweepstakes with $43B Bid
Pfizer will acquire the Seattle-based antibody-drug conjugate leader in a $43 billion deal expected to close late in 2023 or early 2024.
March 13, 2023
 · 
1 min read
 · 
Kate Goodwin
Clene President and CEO Rob Etherington/Courtesy C
Drug Development
Clene’s Nanocrystal ALS Treatment Bounces Back with Positive Data
Despite missing the initial mark, new analysis of Clene’s gold nanocrystal therapy from the HEALEY ALS trial indicates the asset still shows promise.
March 9, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Incoming Bayer CEO Bill Anderson/courtes
Bayer Plans to Double Down on US Pharma R&D in 2023
Bayer plans to substantially increase investment in U.S.-based pharmaceutical R&D, earmarking $1 billion to invest stateside in 2023.
March 9, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Hands together as the company closes bus
Deals
In Tough Market, CODA Quietly Shuts Doors
As life sciences companies feel the burn of the current economy, one Bay Area biotech, CODA Biotherapeutics, quietly shut its doors.
March 8, 2023
 · 
1 min read
 · 
Kate Goodwin
Drug Development
Small Study of BridgeBio’s Dwarfism Drug Indicates Advantage over BioMarin
BridgeBio posted data Monday from its small but highly anticipated Phase II study of infigratinib in achondroplasia - a drug that could give BioMarin a run for its money.
March 7, 2023
 · 
2 min read
 · 
Kate Goodwin
Sarah Silbiger/Getty Images
Policy
FDA Sets July Decision Date for Full Approval of Leqembi
The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.
March 6, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More